Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group - Lionel Adès, Xavier Thomas, Agnes Guerci Bresler, Emmanuel Raffoux, Olivier Spertini, Norbert Vey, Tony Marchand, Christian Récher, Arnaud Pigneux, Stephane Girault, Eric Deconinck, Claude Gardin, Olivier Tournilhac, Jean Francois Lambert, Patrice Chevallier - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Ferrata Storti Foundation, Haematologica, 12(103), p. 2033-2039, 2018

DOI: 10.3324/haematol.2018.198614

Links

Tools

Export citation

Search in Google Scholar

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group

Journal article published in 2018 by Lionel Adès, Xavier Thomas, Agnes Guerci Bresler, Emmanuel Raffoux, Olivier Spertini, Norbert Vey, Tony Marchand, Christian Récher, Arnaud Pigneux, Stephane Girault, Eric Deconinck, Claude Gardin, Olivier Tournilhac, Jean Francois Lambert, Patrice Chevallier and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Red circle

Preprint: archiving forbidden

Red circle

Postprint: archiving forbidden

Green circle

Published version: archiving allowed

Upload

Policy details

Data provided by

SHERPA/RoMEO